Pharmacologic treatment of fibromyalgia

被引:8
作者
Barkhuizen A. [1 ]
机构
[1] Department of Medicine (L329A), Oregon Health Sciences University and Portland VA Medical Center, 3181 SW Sam Jackson Park Road, Portland, 97201, OR
关键词
Fibromyalgia; Interstitial Cystitis; Irritable Bowel Syndrome; Myofascial Pain; Tramadol;
D O I
10.1007/s11916-001-0025-y
中图分类号
学科分类号
摘要
Fibromyalgia is a chronic syndrome characterized by widespread pain, unrefreshed sleep, disturbed mood, and fatigue. Until such time as we have a clearer understanding of the trigger and/or pathophysiologic mechanisms producing these symptoms, pharmacologic treatment should be aimed at individual symptoms. Such treatment should ideally be offered as part of a multidisciplinary treatment program using both pharmacologic and nonpharmacologic treatment modalities. Critical components of any successful fibromyalgia treatment program include addressing physical fitness, work and other functional activities, and mental health, in addition to symptom-specific therapies. The main symptoms that should be addressed include pain, sleep disturbances including restless leg syndrome, mood disturbances, and fatigue. Pharmacologic therapy should also be considered for syndromes commonly associated with fibromyalgia including irritable bowel syndrome, interstitial cystitis, migraine headaches, temporomandibular joint dysfunction, dysequilibrium including neurally mediated hypotension, sicca syndrome, and growth hormone deficiency. This article provides general guidelines in initiating a successful pharmacologic treatment program for fibromyalgia. © 2001, Current Science Inc.
引用
收藏
页码:351 / 358
页数:7
相关论文
共 73 条
[1]  
Bennett R.M., Burckhardt C.S., Clark S.R., Et al., Group treatment of fibromyalgia: a 6-month outpatient program, J Rheumatol, 23, pp. 521-528, (1996)
[2]  
Bennett R.M., Multidisciplinary group programs to treat fibromyalgia patients, Rheum Dis Clin North Am, 22, pp. 351-367, (1996)
[3]  
Russell I.J., Fibromyalgia syndrome: approaches to management, Bull Rheum Dis, 45, pp. 1-4, (1996)
[4]  
Bennett R.M., Campbell S.M., Burckhardt C., Et al., A multidisciplinary approach to fibromyalgia management, J Musculoskeletal Med, 8, pp. 21-32, (1991)
[5]  
Russell I.J., Kamin M., Bennett R.M., Et al., Efficacy of tramadol in treatment of pain in fibromyalgia, J Clin Rheumatol, 6, pp. 250-257, (2000)
[6]  
Bennett R.M., Clark S.R., Walczyk J., A randomized double blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia, Am J Med, 104, pp. 227-231, (1998)
[7]  
Goldenberg D., Mayskiy M., Mossey C., Et al., A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia, Arthritis Rheum, 39, pp. 1852-1859, (1996)
[8]  
Russell I.J., Michalek J.E., Flechas J.D., Abraham G.E., Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study, J Rheumatol, 22, pp. 953-958, (1995)
[9]  
Wolfe F., Cathey M.A., Hawley D.J., A double-blind placebo controlled trial of fluoxetine in fibromyalgia, Scand J Rheumatol, 23, pp. 255-259, (1994)
[10]  
Jacobsen S., Danneskiold-Samsoe B., Anderson R.B., S-adenosylmethionine in primary fibromyalgia: double-blind clinical evaluation, Scand J Rheumatol, 20, pp. 294-302, (1991)